91�Թ�

Can we make human cells and tissues that perform better than nature? Can we reverse aging and make old cells young again? How can we ensure regenerative medicine is available and affordable to everyone?

These are some of the questions researchers will tackle as part of , a $3-million investment in the future of regenerative medicine through research that addresses some of the field’s biggest unanswered questions.

“Our vision is bold. We are looking beyond the current state-of-the-art,” said , executive director of Medicine by Design, and at the and the department of chemical engineering and applied chemistry at the 91�Թ�.

“This is work that will not only shape the future of regenerative medicine and define the field for the next 20 to 30 years, but also transform human health.”

The program seeks to amplify the impact of  by curating research teams with expertise in new and emerging fields such as artificial intelligence and machine learning, synthetic and computational biology, and microfluidics, and engaging Canadian and international advisers.

Regenerative medicine uses stem cells to replace diseased tissues and organs, creating therapies in which cells are the biological product. Regenerative medicine can also mean triggering stem cells that are already present in the human body to repair damaged tissues or to modulate immune responses. Increasingly, regenerative medicine researchers are using a stem cell lens to identify critical interactions or defects that prepare the ground for disease, paving the way for new approaches to preventing disease before it starts.

The ambitious vision for the Grand Questions Program was inspired by initiatives such as and . Its questions are  designed to provoke bold and revolutionary proposals from the community at 91�Թ� and its partner hospitals. These proposals will lead to research that will be of critical importance to regenerative medicine over the next two decades and beyond.

 “Over the past five years, Medicine by Design has brought together leading regenerative medicine researchers across 91�Թ� and its affiliated hospitals to generate groundbreaking discoveries at the convergence of stem cell biology and biomedical engineering,” said Christine Allen, 91�Թ�’s associate vice-president and vice-provost, strategic initiatives.

“The ambition and scope of the Grand Questions Program takes that excellence to the next level and positions Toronto and Canada as a leader in the field. Moreover, the program brings regenerative medicine into a new era – we’re no longer only thinking about treating disease, but actually being able to prevent it before it starts.” 

Planning began last year with community consultations that sought to identify and describe ambitious research questions that were provocative, non-obvious and would excite curiosity and inspire progress.

Following these consultations, which included a workshop in April and follow-on discussions with more than 50 researchers, Medicine by Design’s scientific advisory board narrowed down a long list of questions to the six that they deemed to be the most pressing, unanswered questions in regenerative medicine. 

The until August 14, 2020. The research should have wide-reaching impact, beyond a specific disease or tissue-focused project, and applicants must have a 91�Թ� faculty appointment. Phase one will be a competitive process, and selected applications will receive funding to develop multi-disciplinary teams and prepare a full proposal.

Phase two proposals will be evaluated by external peer reviewers and Medicine by Design’s scientific advisory board. Final funding decisions are expected to be announced in March 2021.